Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435391 | 0.73 | AKR1B1 (0.56) | AKR1B1PGRMEN1KMT2AALDH1A1 | |
| SCHEMBL2199161 | 0.73 | AKR1B1 (0.56) | AKR1B1PGRMEN1KMT2AALDH1A1 | |
| SCHEMBL6206045 | 0.73 | LMNA (0.47) | MAPTAKR1B1ALDH1A1CYP2C19LMNA | |
| SCHEMBL6207024 | 0.73 | LMNA (0.52) | MAPTAKR1B1CCR4MEN1KMT2A | |
| SCHEMBL6229563 | 0.72 | AKR1B1 (0.47) | MAPTAKR1B1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL25248250 | 0.70 | NNMT (0.41) | MAPTALDH1A1CYP2C19LMNAHTT | |
| SCHEMBL10974178 | 0.69 | HSD11B1 (0.61) | MAPTAKR1B1PGRMEN1KMT2A | |
| SCHEMBL4450386 | 0.69 | AKR1B1 (0.61) | AKR1B1CYP1A2CYP2C19 | |
| SCHEMBL6206394 | 0.69 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL10785888 | 0.69 | ALDH1A1 (0.47) | AKR1B1PGRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236720-B1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6872722-B2 | Therapies for tissue damage resulting from ischemia | PFIZER INC (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1260224-B1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | PFIZER PROD INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | MYLARI BANAVARA L (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1260224-A1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1236720-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | MAPT 3741/4885AKR1B1 2/4885PGR 2150/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | MAPT 3891/4885AKR1B1 3/4885PGR 2179/4885 |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | TNNI3, TNNC1, TNNT2 | MAPT 3606/4885AKR1B1 2046/4885PGR 3709/4885 |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | ALDOA, PDXK, AKR1B1 | MAPT 3628/4885AKR1B1 3/4885PGR 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.